Martin Shkreli Faces New Accusations Over High-Priced Drug

A lawsuit by the Federal Trade Commission and New York’s attorney general says his company blocked generic rivals after sharply raising the cost of Daraprim. New York Times By BY CECILIA KANG from NYT Business https://ift.tt/37y7t0L
Antitrust Laws and Competition Issues, Drugs (Pharmaceuticals), Toxoplasmosis